Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors (NCT06233942)

🧪 Interventions in This Study

• BG-C9074 (DRUG)
• Tislelizumab (DRUG)
• Bevacizumab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (37 Sites)

Showing the first 25 of 37 sites.

• Usc Norris Comprehensive Cancer Center (Nccc) — Los Angeles, California
• University of Colorado Cancer Center — Aurora, Colorado
• Florida Cancer Specialist Research Institute Lake Nona — Orlando, Florida
• Sidney Kimmel Comprehensive Cancer At Johns Hopkins — Baltimore, Maryland
• James Cancer Hospital and Solove Research Institute — Columbus, Ohio
• Blacktown Cancer and Haematology Centre — Blacktown, New South Wales
• Macquarie University — North Ryde, New South Wales
• Cancer Care Wollongong — Wollongong, New South Wales
• Princess Alexandra Hospital — Woolloongabba, Queensland
• Monash Health — Clayton, Victoria
• Cabrini Hospital Malvern — Malvern, Victoria
• Peter Maccallum Cancer Centre — Melbourne, Victoria
• Linear Clinical Research — Nedlands, Western Australia
• Hospital Sirio Libanes Brasilia — Brasília,
• Liga Norte Riograndene Contra O Cancer — Natal,
• Hospital Sao Lucas Da Pucrs — Porto Alegre,
• Instituto Nacional de Cancer Hospital Do Cancer Ii — Rio de Janerio,
• Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto — São José do Rio Preto,
• Icesp Instituto Do Cancer Do Estado de Sao Paulo Octavio Frias de Oliveira — São Paulo,
• Clinica de Pesquisa E Centro de Estudos Em Oncologia Ginecologica E Mamaria — São Paulo,
• Cancer Hospital Chinese Academy of Medical Sciences — Beijing, Beijing Municipality
• Fujian Cancer Hospital — Fuzhou, Fujian
• Sun Yat Sen University Cancer Center — Guangzhou, Guangdong
• Harbin Medical University Cancer Hospital — Harbin, Heilongjiang
• Union Hospital of Tongji Medical College, Huazhong University of Science and Technology — Wuhan, Hubei

📞 Contact the Study Coordinator

Phone: (877) 828-5568

Email: clinicaltrials@beonemed.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Advanced Solid Tumor

• Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression — Iowa City, Iowa
• A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors — Glendale, California
• QTX3046 in Patients With KRAS G12D Mutations — Grand Rapids, Michigan
• A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors — Houston, Texas
• First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer — Fullerton, California
• A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors — San Antonio, Texas

Explore by condition: All Advanced Solid Tumor clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.